Pronota and Molecuence announce collaboration in protein biomarker discovery
“We’re finding potential collaborators are increasingly persuaded by our track record of not only being able to identify novel protein biomarkers, but also of taking these successfully through the verification process to show they are true, robust and clinically relevant discoveries. We’re delighted to be working with Molecuence, who are one of the leaders in the field of protein biomarker development for diagnostic applications”, commented Nick McCooke, CEO of Pronota.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.